Compare FedEx Corporation (FDX) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

FDX trades at $290.98, up 0.67% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $6.31 exceeding the $5.96 estimate. Revenue for 2025 was $87.93 billion, with a net income margin of 4.68%. Recent news includes a $300 million order for electric trucks from Harbinger and shareholder approval of executive compensation.

The outlook is mixed: analyst consensus is bullish with a $307.55 price target, but rising fuel costs and geopolitical tensions pose near-term risks. Earnings growth and cost-cutting initiatives support upside, while margin pressure from higher diesel prices and competitive pressures are key concerns for investors.

Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.

The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.